• About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

o2h-ventures

  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

Don’t invest unless you’re prepared to lose all your money invested. This is a high risk investment. You could lose all the money you invest and are unlikely to be protected if something goes wrong. Take 2 mins to learn more

o2h Ventures makes an SEIS Investment into Five Alarm Bio to strengthen anti-ageing science
Feb 28 2023

o2h Ventures is delighted to announce a SEIS investment into Five Alarm Bio, a drug discovery company based in Cambridge, UK, that focuses on novel approaches to anti-aging with a broad potential for therapeutic application. FAB completed its seed investment round, raising over £500K to further its research to test new compounds. Prior to this, FAB received an Innovate UK grant of £360K in 2022 to initiate and support their research work.

Five Alarm Bio (FAB) is developing drug candidates that boost our ability to minimize the effects of aging in humans. Anti-aging science is becoming more relevant than ever. Aging is a major cause of almost all illnesses, and as the population ages, the impact of aging on healthcare and on our wider society is profound. The founders, three highly experienced entrepreneurs, identified a novel approach to addressing this problem and created FAB to discover therapies that target many age-related diseases and disabilities by targeting unexplored mechanisms of aging. 

The investment was made from the ‘o2h Human Health SEIS Fund’ which aims to invest in very early-stage companies covering therapeutic drug opportunities or enabling drug discovery or services.

Sunil Shah, CEO of o2h Ventures, said: “We are delighted to have made this investment alongside Meltwind, Cambridge Angels, and Syndicate Room. The combination of the Scientific Depth of our CSO, William Bains, alongside the practical execution skills of the CEO, Janette Thomas, provides a great team to discover and develop new drugs for age-associated diseases”

Janette Thomas, CEO of Five Alarm Bio, said: “I am thrilled with the confidence shown by the investors in the ideas of the FAB team. I look forward to working with everyone to deliver this innovative and exciting program of research that will lead to much-needed treatments for people in the longer term”

About FAB

Anti-ageing science has enormous potential. Age-related diseases such as immune and neurodegenerative diseases are among the leading causes of disability, suffering and death, and a significant burden on health funding.

Five Alarm Bio is developing a small molecule approach to boost the body’s defense against aging, based on a new understanding of how the chemical damage associated with age accumulates in cells. In addition to a broad range of age-related diseases, Five Alarm Bio sees the relevance of its platform for cosmeceuticals.

Founded in 2016 by three experienced entrepreneurs, Five Alarm Bio is based near Cambridge, UK, and is carrying out research at the Babraham Campus.

For more details, please visit 5Alarmbio (fivealarmbio.com) 

About o2h Ventures

The o2h Ventures ‘Human Health’ SEIS and EIS funds make tax-efficient investments in Pre-Seed and Seed stage companies that address human disease: we fund the development of novel therapeutic treatments; we help build new services and tools offerings throughout the biotech ecosystem, and we spur the creation of software & artificial intelligence that will change healthcare.

The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h Ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.

For more information or to invest in the fund, please visit www.o2hventures.com

Media Contact:

Juhi Shah

Marketing Executive

juhi.shah@o2h.com

 

Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
  • youtube
o2h-ventures
recent press releases
  • o2h-ventures Exciting news as o2h Ventures’ portfolio company Small Pharma, unveils positive top-line results of their Phase IIa clinical trial for treating MDD 31 Jan 2023
  • o2h-ventures o2h Ventures backed Kuano wins Innovate UK funding for designing the next generation of cancer drugs 18 Jan 2023
  • o2h-ventures o2h Ventures invests in Qkine – once again… 22 Dec 2022

Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums.

Your capital is at risk. Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.

o2h-ventures
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.
Useful Links
  • About Us
  • Blog
  • Documents Centre
  • Contact Us
  • Team
News
  • o2h Ventures qualified as a finalist as Best EIS Manager – Specialist at Growth Investor Awards 2023
  • o2h Ventures selected as finalist for best seed VC in UKBAA awards 2023
  • o2h Ventures recognized as a finalist for the EISA Impact Award for 2023
Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
© 2023 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us
This website is a financial promotion approved by o2h Ventures Ltd for the purposes of section 21 Financial Services and Markets Act 2000 relating to the communication of invitations or inducements to engage in investment activity. o2h ventures Limited is regulated and authorised by the Financial Conduct Authority. The FCA firm reference number is 812245 and further information can be found on the Financial Services Register.

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)